Interdisciplinary Working Group for Movement Disorders
Botulinum Toxin in Restless Legs Syndrome—A Randomized Double-Blind Placebo-Controlled Crossover Study: Om Mitta S et al.
Toxins 2018, 10, 401;
doi:10.3390/toxins10100401
doi:10.3390/toxins10100401
Author Details:
1 Department of Neurology, Yale University School of Medicine, New Haven, CT 06510, USA;
duarte.machado@hhchealth.org (D.M.); diana.richardson@va.gov (D.R.); bahman.jabbari@yale.edu (B.J.)
duarte.machado@hhchealth.org (D.M.); diana.richardson@va.gov (D.R.); bahman.jabbari@yale.edu (B.J.)
2 Department of Neurology, Columbia Asia Hospitals, Sarjapur Rd, Bangalore 560102, India
3 Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA; dubey.divyanshu@mayo.edu
4 Department of Neurology, Hartford Healthcare Ayer Neuroscience Institute, Hartford, CT 06066, USA
* Correspondence: neurology.mittal@gmail.com; Tel.: +1-(91)-983-487-9072
Unsere Zertifizierer
